Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 9:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Osteoporosis, Post-menopausal Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effects of Potassium Citrate on Bone Metabolism

NCT00357331
View directory record Official record
Conditions
Bone Diseases, Metabolic, Osteoporosis, Postmenopausal
Interventions
potassium citrate
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
45 Years to 75 Years · Female only
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 11, 2017 · Synced Jun 10, 2026, 9:33 PM EDT
Completed Phase 3 Interventional Results available

Effect of Teriparatide Compared to Risedronate on Back Pain in Women With a Spine Fracture Caused by Osteoporosis

NCT00343252
View directory record Official record
Conditions
Osteoporosis, Postmenopausal, Back Pain, Spinal Fracture
Interventions
teriparatide, risedronate, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older · Female only
Enrollment
712 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
20
States / cities
Birmingham, Alabama • Montgomery, Alabama • Peoria, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated May 25, 2011 · Synced Jun 10, 2026, 9:33 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Prevention of Fracture in Postmenopausal Women

NCT01343004
View directory record Official record
Conditions
Osteoporosis, Postmenopausal Osteoporosis
Interventions
Placebo, BA058 80 mcg, teriparatide
Drug
Lead sponsor
Radius Health, Inc.
Industry
Eligibility
50 Years to 85 Years · Female only
Enrollment
2,463 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
5
States / cities
Lakewood, Colorado • Miami, Florida • North Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Jun 10, 2026, 9:33 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Atenolol for the Prevention of Osteoporosis (APO)

NCT04905277
View directory record Official record
Conditions
Healthy
Interventions
Atenolol 50 MG, Placebo
Drug
Lead sponsor
Sundeep Khosla, M.D.
Other
Eligibility
50 Years to 75 Years · Female only
Enrollment
420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
3
States / cities
Scarborough, Maine • Rochester, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jun 10, 2026, 9:33 PM EDT
Completed Phase 2 Interventional Results available

Parathyroid Hormone (PTH) for Osteoporosis in Postmenopausal Women

NCT00086619
View directory record Official record
Conditions
Postmenopausal Osteoporosis, Osteoporosis
Interventions
synthetic hPTH 1-34
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
46 Years to 85 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 29, 2013 · Synced Jun 10, 2026, 9:33 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Effects of Arzoxifene on Bone Mass and the Uterus

NCT00085956
View directory record Official record
Conditions
Postmenopausal Bone Loss
Interventions
Arzoxifene, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years to 60 Years · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 8, 2007 · Synced Jun 10, 2026, 9:33 PM EDT
Completed Phase 3 Interventional Results available

A Study to Test if TVB-009P is Effective in Relieving Postmenopausal Osteoporosis

NCT04729621
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
TVB-009, Prolia®
Combination Product
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
60 Years to 90 Years · Female only
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
20
States / cities
Phoenix, Arizona • Tucson, Arizona • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Jun 10, 2026, 9:33 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis

NCT01674621
View directory record Official record
Conditions
Post Menopausal Osteoporosis
Interventions
Abaloparatide Transdermal (50 mcg), Abaloparatide Transdermal (100 mcg), Abaloparatide Transdermal (150 mcg), Abaloparatide Injection (80 mcg), Abaloparatide Placebo
Drug
Lead sponsor
Radius Health, Inc.
Industry
Eligibility
Up to 85 Years · Female only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Lakewood, Colorado • Atlanta, Georgia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 15, 2020 · Synced Jun 10, 2026, 9:33 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Prunes Preventing Bone Loss in Perimenopause

NCT07120997
View directory record Official record
Conditions
Perimenopausal Bone Loss
Interventions
Prunes, Calcium supplement, Vitamin D Supplement
Dietary Supplement
Lead sponsor
Penn State University
Other
Eligibility
44 Years to 55 Years · Female only
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Jun 10, 2026, 9:33 PM EDT
Completed Phase 4 Interventional Results available

A Study Using Imaging Technology to Measure Changes in Bone Structure After Treatment With Teriparatide

NCT00557310
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
teriparatide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years to 85 Years · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
5
States / cities
Tucson, Arizona • Lakewood, Colorado • Omaha, Nebraska + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2011 · Synced Jun 10, 2026, 9:33 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone

NCT04467983
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Denosumab Injection, Abaloparatide
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
45 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jun 10, 2026, 9:33 PM EDT
Active, not recruiting Phase 2 Interventional

A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS)

NCT06577935
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
AGA2118, Placebo
Drug · Other
Lead sponsor
Angitia Biopharmaceuticals
Industry
Eligibility
55 Years to 80 Years · Female only
Enrollment
379 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
5
States / cities
Birmingham, Alabama • Gainesville, Georgia • Albuquerque, New Mexico + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Jun 10, 2026, 9:33 PM EDT
Completed Phase 4 Interventional Results available

Acetaminophen or Fluvastatin Compared to Placebo on the Transient Post-Dose Symptoms (PDS) Following an Intravenous (i.v.) Infusion of a Single Dose of Zoledronic Acid 5mg, in Post-menopausal Women With Low Bone Mass

NCT00489424
View directory record Official record
Conditions
Osteoporosis
Interventions
Placebo, Acetaminophen, Fluvastatin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
45 Years to 79 Years · Female only
Enrollment
793 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Http://www.osteoporosisclinicalresearch.com, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 17, 2011 · Synced Jun 10, 2026, 9:33 PM EDT
Completed Phase 3 Interventional

Effects of Parathyroid Hormone in Men With Osteoporosis

NCT00000427
View directory record Official record
Conditions
Osteoporosis
Interventions
Parathyroid hormone, Alendronate
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
46 Years to 85 Years · Male only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 8, 2013 · Synced Jun 10, 2026, 9:33 PM EDT
Completed Phase 3 Interventional Results available

MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis

NCT00048061
View directory record Official record
Conditions
Post Menopausal Osteoporosis
Interventions
Ibandronate [Bonviva/Boniva], Calcium, Vitamin D
Drug · Dietary Supplement
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
55 Years to 80 Years · Female only
Enrollment
1,609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
20
States / cities
Irvine, California • Loma Linda, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2018 · Synced Jun 10, 2026, 9:33 PM EDT
Completed Phase 3 Interventional Results available

Efficacy & Safety of Abaloparatide-Solid Microstructured Transdermal System in Postmenopausal Women With Osteoporosis

NCT04064411
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
abaloparatide, abaloparatide solid microstructured transdermal system
Combination Product
Lead sponsor
Radius Health, Inc.
Industry
Eligibility
50 Years to 85 Years · Female only
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
77
States / cities
Birmingham, Alabama • Anchorage, Alaska • Glendale, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Jun 10, 2026, 9:33 PM EDT
Completed Phase 3 Interventional Results available

A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis

NCT00541658
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
risedronate
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
50 Years and older · Female only
Enrollment
923 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
20
States / cities
Birmingham, Alabama • Oakland, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2013 · Synced Jun 10, 2026, 9:33 PM EDT
Completed Phase 4 Interventional Results available

A Study of Ibandronate (Boniva) to Evaluate Bone Turnover Markers in Women With Treatment-Naive Postmenopausal Osteoporosis

NCT02598934
View directory record Official record
Conditions
Post Menopausal Osteoporosis
Interventions
Ibandronate
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Female only
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
50
States / cities
Montgomery, Alabama • Chandler, Arizona • Peoria, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2016 · Synced Jun 10, 2026, 9:33 PM EDT
Completed Phase 3 Interventional

TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis

NCT00172081
View directory record Official record
Conditions
Osteoporosis
Interventions
placebo, ALX1-11
Drug
Lead sponsor
Shire
Industry
Eligibility
45 Years and older · Female only
Enrollment
2,532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
107
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 95 more
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Jun 10, 2026, 9:33 PM EDT
Completed Phase 3 Interventional Results available

Heartland Osteoporosis Prevention Study

NCT02186600
View directory record Official record
Conditions
Osteopenia
Interventions
Calcium Carbonate, Vitamin D3, Risedronate, Bone-loading exercises
Drug · Behavioral
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older · Female only
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Jun 10, 2026, 9:33 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study of 2 Different Formulations of Blosozumab (LY2541546) in Post Menopausal Women

NCT02337387
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Blosozumab, Placebo
Biological · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
3
States / cities
Daytona Beach, Florida • Evansville, Indiana • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 21, 2019 · Synced Jun 10, 2026, 9:33 PM EDT
Completed Phase 3 Interventional

Risedronate 75mg Dosed on 2 Consecutive Days Monthly in the Treatment of Osteoporosis in Postmenopausal Women

NCT00358176
View directory record Official record
Conditions
Osteoporosis Postmenopausal
Interventions
Risedronate (HMR4003)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older · Female only
Enrollment
1,231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 14, 2009 · Synced Jun 10, 2026, 9:33 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Comparison Study of PTHrP and PTH to Treat Osteoporosis

NCT00853723
View directory record Official record
Conditions
Osteoporosis
Interventions
Parathyroid hormone related protein(1-36), Parathyroid hormone (1-34)
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
45 Years to 75 Years · Female only
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 23, 2016 · Synced Jun 10, 2026, 9:33 PM EDT
Completed Not applicable Interventional

Strength Training for Older Breast Cancer Survivors

NCT00591747
View directory record Official record
Conditions
Breast Neoplasm, Osteoporosis, Postmenopausal
Interventions
Resistance Exercise, Flexibility Training
Behavioral
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
50 Years to 90 Years · Female only
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Jun 10, 2026, 9:33 PM EDT